Physician profile
Walter David Smith
NPI 1245664531
$2,527.43
in general payments reported to CMS, 2019-2025
13 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2022: $410 · 2023: $500 · 2024: $480 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $735.35 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.03 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $239.39 | 2019-2022 | |
| Alkermes, INC. | $188.32 | 2022 | |
| Abbvie INC. | $176.04 | 2022-2023 | Vraylar |
| Lilly USA, LLC | $125.00 | 2025 | Zepbound |
| Sunovion Pharmaceuticals INC. | $119.99 | 2019 | |
| Mdd US Operations, LLC | $117.88 | 2025 | Qelbree |
| Neurocrine Biosciences, INC. | $116.02 | 2023 | Ingrezza |
| Axsome Therapeutics, INC. | $109.74 | 2024 | Auvelity |
| Allergan, INC. | $107.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $101.67 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $14.92 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.